NCAPD2

Across TCGA pan-cancer cohorts, NCAPD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NCAPD2 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher NCAPD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NCAPD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, COAD, and CCRCC are the cancer types where NCAPD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.891	0.503	<.001	43	view →
COAD	DFS	Tertile	All	0.905	1.000	.037	12	view →
CCRCC	DFS	Quartile	II,III,IV	0.635	1.000	.012	10	view →
OV	DFS	Median	All	0.869	1.000	.042	4	view →
LUAD	OS	Quartile	II,III,IV	0.304	0.839	.022	4	view →
PDAC	DFS	Tertile	IV	0.777	0.221	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NCAPD2–LSCC (DFS)

Open the LSCC breakdown →